A Phase 3 interventional study of Ubrogepant and Placebo-matching Ubrogepant in Migraine, With or Without Aura, sponsored by Allergan. Completed at 177 sites in United States. Open to participants aged 18 Years to 76 Years. Per ClinicalTrials.gov, last updated 2019-08-28.
Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing ubrogepant in Migraine Disorders — 2 open to participants now, 4 under way, 3 of them phase 3. ubrogepant · Migraine Disorders.
Among the 14 studies testing ubrogepant in Migraine Disorders, this one is the 3rd largest by enrollment, is one of 3 that started in 2016, is one of 7 in phase 3, and was the 5th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
Browse Migraine Disorders studies →2 of the 14 studies testing ubrogepant in Migraine Disorders are open now, in 2 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Puerto Rico
Ages 6–17
AbbVie · Sites in United States, Puerto Rico
Ages 6–17
By country, each count listing its studies:
ubrogepant: first FDA approval 2019 (UBRELVY). What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 76 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,254 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 507 across the 14 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 4 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
55 studies in Migraine Disorders by AbbVie: 9 open now, 13 under way, 7 of them phase 3. Of 40 finished, 32 (80%) have results posted.
Among the 55 studies in Migraine Disorders by AbbVie, this one is the 4th largest by enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2016, is one of 30 in phase 3, and was the 20th registered.
AbbVie’s Migraine Disorders studies by the year they started, since 2006.
2 of the studies testing ubrogepant in Migraine Disorders that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05125302Phase 3AbbVieStudy to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | 2027-05 |
| NCT06417775Phase 3AbbVieStudy of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing ubrogepant in Migraine Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 55 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.
Usual care is the open-label control arm. Dose of ubrogepant (50 mg or 100 mg) will be double-blind for active treatment arms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Completed study UBR-MD-01(NCT02828020) or UBR-MD-02(NCT02867709).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of migraine attacks for up to 1 year.
Drug: Usual Care
Ubrogepant 50 mg tablet orally plus placebo-matching ubrogepant tablet for the treatment of a qualifying migraine attack for up to 8 treatments every 4 weeks for up to 1 year. Participants may choose to take a second dose orally after the initial dose if migraine continues or returns.
Drug: Ubrogepant · Drug: Placebo-matching Ubrogepant
Ubrogepant 100 mg (two 50 mg tablets) orally for the treatment of a qualifying migraine attack for up to 8 treatments every 4 weeks for up to 1 year. Participants may choose to take a second dose orally after the initial dose if migraine continues or returns.
Drug: Ubrogepant
Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Ubrogepant placebo-matching tablet orally for the treatment of a qualifying migraine attack.
Treatment for a migraine as prescribed by the physician as standard of care in clinical practice.
Percentage of Participants With at Least 1 Treatment Emergent Adverse Event
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs are AEs with an onset that occurs after receiving study drug.
Time frame: 56 Weeks
Number of Participants With Clinically Significant Laboratory Values
Hematology, Chemistry and Urinalysis results considered potentially clinically significant (PCS) meeting either the lower-limit or higher-limit PCS criteria.
Time frame: 56 Weeks
Number of Participants With Clinically Significant Electrocardiograms (ECGs) Findings
ECG findings considered potentially clinically significant (PCS) meeting either the lower-limit or higher-limit PCS criteria.
Time frame: 56 Weeks
Number of Participants With Clinically Significant Vital Sign Measurements
Vital sign measurements considered potentially clinically significant (PCS) meeting either the lower-limit or higher-limit PCS criteria.
Time frame: 56 Weeks
Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Using 5-Point Scales
On the C-SSRS, the 5 types of suicidal ideation are: Type 1: "Wish to be dead" Type 2: Non-specific active suicidal thoughts Type 3: "Active suicidal ideation with any methods (not plan) without intent to act" Type 4: "Active suicidal ideation with some intent to act, without specific plan" Type 5: "Active suicidal ideation with specific plan and intent"
Time frame: 56 Weeks
| Milestone | Usual Care | Ubrogepant 50 mg | Ubrogepant 100 mg |
|---|---|---|---|
| Started | 417 | 417 | 420 |
| Safety population: received study drug | 417 | 404 | 409 |
| Completed | 329 | 291 | 315 |
| Not completed | 88 | 126 | 105 |
| Withdrew: Other miscellaneous reasons | 0 | 2 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 3 | 2 |
| Withdrew: Protocol violation | 2 | 5 | 8 |
| Withdrew: Pregnancy | 4 | 6 | 3 |
| Withdrew: Lack of qualifying event | 0 | 3 | 1 |
| Withdrew: Withdrawal of consent | 52 | 51 | 41 |
| Withdrew: Lack of efficacy | 0 | 17 | 12 |
| Withdrew: Adverse event | 4 | 9 | 11 |
| Withdrew: Lost to follow-up | 26 | 30 | 26 |
| Milestone | Usual Care | Ubrogepant 50 mg | Ubrogepant 100 mg |
|---|---|---|---|
| Started | 350 | 356 | 364 |
| Completed | 343 | 339 | 350 |
| Not completed | 7 | 17 | 14 |
| Withdrew: Other miscellaneous reasons | 0 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 3 | 5 | 5 |
| Withdrew: Withdrawal of consent | 4 | 10 | 8 |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs are AEs with an onset that occurs after receiving study drug.
| Percentage of Participants | Usual Care | Ubrogepant 50 mg | Ubrogepant 100 mg |
|---|---|---|---|
| Percentage of Participants With at Least 1 Treatment Emergent Adverse Event | 65 | 66.3 | 72.6 |
Hematology, Chemistry and Urinalysis results considered potentially clinically significant (PCS) meeting either the lower-limit or higher-limit PCS criteria.
| Participants | Usual Care | Ubrogepant 50 mg | Ubrogepant 100 mg |
|---|---|---|---|
| Basophils Absolute Cell Count (10**9/L) >2×ULN | 0 | 0 | 0 |
| Eosinophils Absolute Cell Count (10**9/L) >2×ULN | 1 | 0 | 1 |
| Hematocrit (RATIO) <0.9×LLN | 3 | 2 | 6 |
| Hematocrit (RATIO) >1.1×ULN | 2 | 0 | 1 |
| Hemoglobin (g/L) <0.9×LLN | 7 | 3 | 6 |
| Hemoglobin (g/L) >1.1×ULN | 2 | 0 | 1 |
| Lymphocytes Absolute Cell Count (10**9/L) <0.7×LLN | 11 | 5 | 5 |
| Lymphocytes Absolute Cell Count (10**9/L) >1.3×ULN | 8 | 6 | 8 |
| Monocytes Absolute Cell Count (10**9/L) <0.5×LLN | 0 | 0 | 0 |
| Monocytes Absolute Cell Count (10**9/L) >2×ULN | 0 | 0 | 0 |
| Neutrophils Absolute Cell Count (10**9/L) <0.7×LLN | 6 | 5 | 6 |
| Neutrophils Absolute Cell Count (10**9/L) >1.3×ULN | 22 | 14 | 17 |
| Platelet Count (Thrombocytes) (10**9/L) <0.5×LLN | 0 | 0 | 0 |
| Platelet Count (Thrombocytes) (10**9/L) >1.5×ULN | 2 | 2 | 1 |
| Red Blood Cell Count (10**12/L) <0.9×LLN | 1 | 5 | 3 |
| Red Blood Cell Count (10**12/L) >1.1×ULN | 2 | 2 | 2 |
| White Blood Cell Count (10**9/L) <0.9×LLN | 17 | 9 | 17 |
| White Blood Cell Count (10**9/L) >1.5×ULN | 5 | 2 | 4 |
| Alanine Aminotransferase (SGPT) (U/L) >3×ULN | 4 | 4 | 8 |
| Albumin (g/L) <0.8×LLN | 0 | 1 | 0 |
| Albumin (g/L) >1.2×ULN | 0 | 0 | 0 |
| Alkaline Phosphatase (U/L) >3×ULN | 0 | 0 | 0 |
| Aspartate Aminotransferase (SGOT) (U/L) >3×ULN | 2 | 2 | 9 |
| Bicarbonate (HCO3) (mmol/L) <0.9×LLN | 25 | 22 | 37 |
| Bicarbonate (HCO3) (mmol/L) >1.1×ULN | 0 | 0 | 0 |
| Bilirubin, Total (umol/L) >1.5×ULN | 3 | 4 | 2 |
| Blood Urea Nitrogen (mmol/L) >1.5×ULN | 6 | 3 | 1 |
| Calcium (mmol/L) <0.9×LLN | 2 | 1 | 3 |
| Calcium (mmol/L) >1.1×ULN | 0 | 0 | 0 |
| Chloride (mmol/L) <0.9×LLN | 0 | 0 | 1 |
| Chloride (mmol/L) >1.1×UL | 0 | 0 | 0 |
| Cholesterol, Total (mmol/L) >1.6×ULN | 4 | 1 | 2 |
| Creatine Kinase (U/L) >2×ULN | 56 | 43 | 57 |
| Creatinine (umol/L) >1.5×ULN | 1 | 1 | 1 |
| Glucose, Non-fasting (mmol/L) <0.8×LLN | 0 | 0 | 0 |
| Glucose, Non-fasting (mmol/L) >2×ULN | 1 | 1 | 1 |
| Lactate Dehydrogenase (U/L) >3×ULN | 0 | 0 | 0 |
| Phosphorus (mmol/L) <0.9×LLN | 45 | 38 | 42 |
| Phosphorus (mmol/L) >1.1×ULN | 21 | 15 | 21 |
| Potassium (mmol/L) <0.9×LLN | 0 | 1 | 3 |
| Potassium (mmol/L) >1.1×ULN | 28 | 32 | 33 |
| Protein, Total (g/L) <0.9×LLN | 3 | 2 | 4 |
| Protein, Total (g/L) >1.1×ULN | 0 | 0 | 0 |
| Sodium (mmol/L) <0.9×LLN | 0 | 0 | 0 |
| Sodium (mmol/L) >1.1×ULN | 0 | 0 | 2 |
| Triglycerides (mmol/L) >2×ULN | 30 | 20 | 17 |
| Uric Acid (Urate) (umol/L) >1.2×ULN | 26 | 27 | 22 |
| Glucose Positive | 21 | 17 | 23 |
| pH (pH) <0.9×LLN | 0 | 0 | 0 |
| pH (pH) >1.1×ULN | 0 | 0 | 0 |
| Protein (g/L) Positive | 0 | 0 | 0 |
| Specific Gravity >1.1×ULN | 0 | 0 | 0 |
ECG findings considered potentially clinically significant (PCS) meeting either the lower-limit or higher-limit PCS criteria.
| Participants | Usual Care | Ubrogepant 50 mg | Ubrogepant 100 mg |
|---|---|---|---|
| PR interval (msec) PR >= 250 | 0 | 0 | 0 |
| QRS interval (msec) QRS >= 150 | 1 | 1 | 0 |
| QTc Bazett (msec) QTcB > 500 | 0 | 0 | 0 |
| QTc Bazett (msec) Increase > 60 (msec) | 0 | 1 | 5 |
| QTc Fridericia (msec) QTcF > 500 | 0 | 0 | 0 |
| QTc Fridericia (msec) Increase > 60 (msec) | 1 | 0 | 0 |
Vital sign measurements considered potentially clinically significant (PCS) meeting either the lower-limit or higher-limit PCS criteria.
| Participants | Usual Care | Ubrogepant 50 mg | Ubrogepant 100 mg |
|---|---|---|---|
| SBP (mmHg) (Sitting) <= 90 and Decrease of >= 20 | 11 | 20 | 12 |
| SBP (mmHg) (Sitting) >= 180 and Increase of >= 20 | 0 | 0 | 1 |
| SBP (mmHg) (Standing) <= 90 and Decrease of >= 20 | 12 | 11 | 11 |
| SBP (mmHg) (Standing) >= 180 and Increase of >= 20 | 0 | 0 | 1 |
| Standing - Sitting SBP (mmHg) <= -20 | 58 | 40 | 49 |
| DBP (mmHg) (Sitting) <= 50 and Decrease of >= 15 | 6 | 5 | 4 |
| DBP (mmHg) (Sitting) >= 105 and Increase of >= 15 | 6 | 3 | 6 |
| DBP (mmHg) (Standing) <= 50 and Decrease of >= 15 | 5 | 4 | 4 |
| DBP (mmHg) (Standing) >= 105 and Increase of >= 15 | 12 | 14 | 11 |
| Standing - Sitting DBP (mmHg) <= -15 | 38 | 42 | 36 |
| PR (beats/min) (Sitting) <= 50, Decrease of >= 15 | 4 | 5 | 7 |
| PR (beats/min) (Sitting) >= 120, Increase of >= 15 | 1 | 2 | 1 |
| PR (beats/min) (Standing) <= 50, Decrease of >= 15 | 2 | 3 | 3 |
| PR (beats/min)(Standing) >= 120, Increase of >= 15 | 14 | 9 | 13 |
| Standing - Sitting Pulse Rate (beats/min) >= 25 | 42 | 37 | 35 |
| Weight (kg) Decrease of >= 7% | 58 | 48 | 53 |
| Weight (kg) Increase of >= 7% | 73 | 69 | 61 |
On the C-SSRS, the 5 types of suicidal ideation are: Type 1: "Wish to be dead" Type 2: Non-specific active suicidal thoughts Type 3: "Active suicidal ideation with any methods (not plan) without intent to act" Type 4: "Active suicidal ideation with some intent to act, without specific plan" Type 5: "Active suicidal ideation with specific plan and intent"
| Participants | Usual Care | Ubrogepant 50 mg | Ubrogepant 100 mg |
|---|---|---|---|
| Suicidal Ideation | 5 | 3 | 2 |
| Suicidal Behavior | 0 | 0 | 0 |
Collected over Adverse events were collected up to 56 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Usual Care | 0/417 (0%) | 17/417 (4.1%) | 132/417 (31.7%) |
| Ubrogepant 50 mg | 0/404 (0%) | 9/404 (2.2%) | 125/404 (30.9%) |
| Ubrogepant 100 mg | 0/409 (0%) | 12/409 (2.9%) | 138/409 (33.7%) |
| Event | Usual Care | Ubrogepant 50 mg | Ubrogepant 100 mg |
|---|---|---|---|
| Cholecystitis acuteHepatobiliary disorders | 0/417 | 1/404 | 1/409 |
| CholelithiasisHepatobiliary disorders | 1/417 | 1/404 | 1/409 |
| PneumoniaInfections and infestations | 1/417 | 1/404 | 1/409 |
| Device allergyImmune system disorders | 0/417 | 1/404 | 0/409 |
| Gait disturbanceGeneral disorders | 0/417 | 1/404 | 0/409 |
| Hypertensive crisisVascular disorders | 0/417 | 1/404 | 0/409 |
| Intestinal obstructionGastrointestinal disorders | 0/417 | 1/404 | 0/409 |
| Pelvic inflammatory diseaseInfections and infestations | 0/417 | 1/404 | 0/409 |
| Post procedural infectionInfections and infestations | 1/417 | 1/404 | 0/409 |
| Sinus tachycardiaCardiac disorders | 0/417 | 1/404 | 0/409 |
| Event | Usual Care | Ubrogepant 50 mg | Ubrogepant 100 mg |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 48/417 | 47/404 | 44/409 |
| NasopharyngitisInfections and infestations | 33/417 | 33/404 | 47/409 |
| SinusitisInfections and infestations | 25/417 | 28/404 | 26/409 |
| Urinary tract infectionInfections and infestations | 23/417 | 22/404 | 26/409 |
| InfluenzaInfections and infestations | 21/417 | 17/404 | 25/409 |
Intent-to-Treat (ITT) population included all randomized participants.
| Age, Continuous(Years) | Usual Care | Ubrogepant 50 mg | Ubrogepant 100 mg | Total |
|---|---|---|---|---|
| Mean | 41.7 ± 11.7 | 42.2 ± 12.2 | 41.2 ± 11.2 | 41.7 ± 11.7 |
| Sex: Female, Male(Participants) | Usual Care | Ubrogepant 50 mg | Ubrogepant 100 mg | Total |
|---|---|---|---|---|
| Female | 367 | 384 | 375 | 1126 |
| Male | 50 | 33 | 45 | 128 |
| Race/Ethnicity, Customized(Participants) | Usual Care | Ubrogepant 50 mg | Ubrogepant 100 mg | Total |
|---|---|---|---|---|
| White | 356 | 358 | 345 | 1059 |
| Black or African American | 50 | 52 | 61 | 163 |
| Asian | 3 | 2 | 5 | 10 |
| American Indian or Alaska Native | 4 | 2 | 3 | 9 |
| Native Hawaiian/Other Pacific Islander | 0 | 1 | 2 | 3 |
| Multiple | 4 | 2 | 4 | 10 |
| Race/Ethnicity, Customized(Participants) | Usual Care | Ubrogepant 50 mg | Ubrogepant 100 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 62 | 64 | 59 | 185 |
| Not Hispanic or Latino | 355 | 353 | 361 | 1069 |
Showing the first 100 of 177 sites. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2016 to primary completion in Aug 2018, 22 months.
Results were first posted in Aug 2019, 1 year after primary completion.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 22 months is above that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ubrogepant